Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hyloris Pharmaceuticals S.A. (HYL.BR)
Liège, BE
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.40% | +0.40% | +3.51% | -29.69% | -16.05% | -26.61% | -14.92% | -56.16% | -65.38% | -51.68% | -51.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-28.2% Q2'25: -28.0% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%-4.6% Q2'25: -8.3% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-131.5% Q2'25: -100.1% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%-129.5% Q2'25: -105.5% (vs Q2'24)
-
ROIC Biotechnology: -16.1%-64.8% Q2'25: -48.9% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%-5.2% ★ Q2'25: -5.8% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.20× Q2'25: -0.26× (vs Q2'24)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
175.0K
est: 800.0K (-78.1%)
|
3.10M
est: 2.25M (+37.6%)
|
2.95M
est: 2.70M (+9.3%)
|
2.09M
est: 6.94M (-69.9%)
|
10.04M
est: 7.05M (+42.4%)
|
7.21M
est: 9.14M (-21.2%)
|
25.70M
9.60M – 41.80M
+181.1% YoY
|
72.35M
50.52M – 109.44M
+181.5% YoY
|
170.10M
103.20M – 262.76M
+135.1% YoY
|
| EBITDA |
-6.17M
est: -717.2K (-760.7%)
|
-10.78M
est: -2.02M (-434.4%)
|
-11.43M
est: -2.42M (-372.3%)
|
-14.98M
est: -6.22M (-140.7%)
|
-4.85M
est: -6.32M (+23.3%)
|
-8.42M
est: -8.20M (-2.7%)
|
-23.04M
-37.48M – -8.61M
-181.1% YoY
|
-64.87M
-98.12M – -45.29M
-181.5% YoY
|
-152.50M
-235.58M – -92.53M
-135.1% YoY
|
| EBIT |
-6.27M
est: -736.8K (-751.5%)
|
-10.90M
est: -2.07M (-425.7%)
|
-11.92M
est: -2.49M (-379.4%)
|
-15.33M
est: -6.39M (-139.8%)
|
-6.08M
est: -6.49M (+6.4%)
|
-9.34M
est: -8.42M (-10.8%)
|
-23.67M
-38.50M – -8.84M
-181.1% YoY
|
-66.64M
-100.80M – -46.53M
-181.5% YoY
|
-156.67M
-242.01M – -95.05M
-135.1% YoY
|
| Net Income |
-7.15M
est: -31.66M (+77.4%)
|
-11.58M
est: -12.78M (+9.4%)
|
-11.91M
est: -12.46M (+4.5%)
|
-15.38M
est: -13.24M (-16.1%)
|
-6.34M
est: -17.24M (+63.2%)
|
-6.33M
est: -6.33M (+0.0%)
|
-7.68M
-21.93M – -903.9K
-21.2% YoY
|
12.82M
-11.65M – 34.21M
+267.0% YoY
|
89.70M
43.07M – 150.53M
+599.6% YoY
|
| SGA |
2.19M
est: 2.86M (-23.3%)
|
2.90M
est: 8.05M (-64.0%)
|
3.52M
est: 9.66M (-63.6%)
|
5.55M
est: 8.18M (-32.2%)
|
5.63M
est: 8.31M (-32.3%)
|
3.96M
est: 10.78M (-63.2%)
|
30.31M
11.32M – 49.29M
+181.1% YoY
|
85.32M
59.57M – 129.06M
+181.5% YoY
|
200.59M
121.70M – 309.86M
+135.1% YoY
|
| EPS |
-0.28
est: -1.09 (+74.3%)
|
-0.45
est: -0.44 (-2.3%)
|
-0.44
est: -0.77 (+42.9%)
|
-0.55
est: -0.47 (-18.2%)
|
-0.22
est: -0.57 (+61.4%)
|
-0.23
est: -0.24 (+4.0%)
|
-0.32
-0.80 – -0.03
-31.4% YoY
|
0.46
-0.42 – 1.24
+244.4% YoY
|
3.20
1.56 – 5.47
+603.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stijn Van Rompay | Co-Founder, CEO & Director | 212.8K | male |
| Ann De Jaeger | Chief Legal Officer & General Secretary | — | female |
| Christophe Marechal | Chief Financial Officer | — | male |
| Dietmar Aichhorn | Chief Operating Officer | — | — |
| Thomas Jacobsen | Co-Founder, Chief Business Development Officer & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HYL.BR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
